BITTER TASTE RECEPTORS ARE EXPRESSED AND FUNCTIONAL IN BOTH HSC AND LEUKEMIC CELLS
EHA Library, Valentina Salvestrini, 294415
MEDS433; NEW GENERATION OF DIHYDROOROTATE DEHYDROGENASE (DHODH) INHIBITOR IN THE TREATMENT OF AML
EHA Library, Mohammad Houshmand, 294416
THERAPEUTIC POTENTIAL OF TENALISIB, A PI3K DELTA/GAMMA PLUS SIK-3 INHIBITOR, IN HEMATOLOGICAL MALIGNANCIES
EHA Library, Srikant Viswanadha, 294417
IDENTIFICATION OF POTENTIAL BIOMARKER FOR PREDICTING THE RESPONSE OF AML CELLS TO LYSINE SPECIFIC DEMETHYLASE 1 (LSD1) INHIBITORS
EHA Library, Amal Kamal Abdel-Aziz, 294418
COMPARATIVE TRANSCRIPTIONAL SIGNATURE OF PURIFIED ERYTHROBLASTS FROM ACUTE MYELOID LEUKEMIA AML 6A (FAB CLASSIFICATION) AND PURE ERYTHROID LEUKEMIA USING NANOSTRING TECHNOLOGY
EHA Library, A Caulier, 294419
PYRVINIUM PAMOATE PROMOTES CELL DEATH ASSOCIATED WITH INTEGRATED STRESS RESPONSE ON ACUTE MYELOID LEUKEMIA CELLS
EHA Library, Yu-Hsuan Fu, 294420
EARLY DETERMINATION OF THE MEASURABLE RESIDUAL DISEASE AFTER ALLOGENEIC TRANSPLANT CARRIES PROGNOSTIC IMPLICATIONS IN ACUTE MYELOID LEUKEMIA
EHA Library, Claudia Nunez-Torron Stock, 294421
ASTX295, A NOVEL SMALL MOLECULE MDM2 ANTAGONIST, DEMONSTRATES POTENT ACTIVITY IN AML IN COMBINATION WITH DECITABINE
EHA Library, Luke Bevan, 294423
BISPECIFIC T-CELL ENGAGER ANTIBODIES MAY CONTRIBUTE TO REACTIVATE PRE-EXISTING TUMOR SPECIFIC T-CELLS
EHA Library, Joan Ballesteros, 294424
MINIMAL RESIDUAL DISEASE AND COMPLETE MOLECULAR EVALUATION IN NPM1 MUTATED ACUTE MYELOID LEUKEMIA: A SINGLE CENTER STUDY
EHA Library, Mara Memoli, 294425
THE ONCOPROTEIN SKI IS ASSOCIATED WITH A SHORTER OVERALL SURVIVAL IN ACUTE MYELOID LEUKEMIA PATIENTS WITH NORMAL KARYOTYPE AND A MUTATED RECEPTOR TYROSINE KINASE FLT3ITD
EHA Library, Miriam Frech, 294426
SINGLE CELL PROFILING OF BCL-2 FAMILY MEMBERS AND CLEAVED CASPASE-3 IN SEARCH OF BIOMARKERS FOR VENETOCLAX TREATMENT IN ACUTE MYELOID LEUKEMIA
EHA Library, Oda Helen Eck Fagerholt, 294427
PREFERENTIAL TRANSCRIPTION AND TARGETING OF THE MUTATED ALLELE IN NPM1 MUTATED ACUTE MYELOID LEUKAEMIA
EHA Library, Graham Bailey, 294428
ANALYTICAL PERFORMANCES OF RNA SEQUENCING FOR THE DIAGNOSIS OF HAEMATOLOGICAL MALIGNANCIES
EHA Library, Sarah Huet, 294429
LEF1-AS1, LONG NON-CODING RNA, IS A NEW PLAYER IN HUMAN ERYTHROID DIFFERENTIATION
EHA Library, Ada Congrains Castillo, 294430
RADICICOL AS A MODULATOR TO REVERT WARBURG EFFECT ON CABOZANTINIB-RESISTANT MYELOID LEUKEMIA CELLS WITH FLT3-ITD
EHA Library, Yu-Hsuan Fu, 294431
INVESTIGATION OF NUCLEOPHOSMIN1 AND IDH MUTATIONS BY DIGITAL DROPLET PCR IN ACUTE MYELOID LEUKEMIA
EHA Library, Petra Kovy, 294432
HIGH MUTANT ALLELE BURDEN OF ASXL1 GENE IS A POOR PROGNOSIS FACTOR FOR ADULT ACUTE MYELOID LEUKEMIA
EHA Library, Yanfang Liu, 294433
COMPUTATIONAL APPROACHES FOR RESIDUAL DISEASE MONITORING IN ACUTE MYELOID LEUKEMIA
EHA Library, Costa Bachas, 294434
HARNESSING GENE EXPRESSION PROFILES FOR THE IDENTIFICATION OF DRUG RESISTANCE GENES IN PEDIATRIC ACUTE MYELOID LEUKEMIA
EHA Library, David GJ Cucchi, 294435
BIOLOGY OF T(6;11) FUSION GENES AND THEIR ROLE IN MLL-REARRANGED ACUTE LEUKEMIA LINEAGE DETERMINATION
EHA Library, Arpita Kundu, 294436
QUANTITATIVE EVALUATION AND MONITORING OF RESIDUAL DISEASE USING WILMS' TUMOR 1 (WT1) GENE EXPRESSION IN ACUTE MYELOID LEUKEMIA TREATED WITH DECITABINE
EHA Library, Anna Candoni, 294437
EXPOSURE-MACROPHAGE INHIBITORY CYTOKINE-1 (MIC-1) RESPONSE ANALYSIS OF THE MDM2 ANTAGONIST KRT-232 IN PATIENTS WITH ADVANCED SOLID TUMORS, MULTIPLE MYELOMA, OR ACUTE MYELOID LEUKEMIA
EHA Library, Martine Allard, 294438
GALECTIN-9 OVERCOMES THERAPY RESISTANCE IN ACUTE MYELOID LEUKEMIA
EHA Library, Valerie Wiersma, 294439
ADVANTAGES AND LIMITATIONS OF CULTURED MESENCHYMAL STROMAL CELLS (MSC) FROM ACUTE MYELOID LEUKEMIA (AML) PATIENTS AS A SOURCE OF GERMLINE DNA FOR SEQUENCING STUDIES
EHA Library, F Guijarro, 294440
EVOLUTION OF STEM CELL FREQUENCY AND CORRELATION WITH THE IMMUNOPHENOTYPE DURING SERIAL TRANSPLANTATION IN A CALM/AF10 LEUKEMIA MODEL
EHA Library, Niloofar Zandvakili, 294442
CHAPERONE-MEDIATED AUTOPHAGY IN NORMAL AND ACUTE MYELOID LEUKEMIA GRANULOCYTIC DIFFERENTIATION
EHA Library, Sreoshee Rafiq, 294443
GENETIC CHARACTERIZATION OF ACUTE MYELOID LEUKAEMIA PATIENTS WITH MUTATIONS IN IDH1/2 GENES
EHA Library, Pamela Acha, 294444
EFFECT OF HISTONE DEACETYLASE INHIBITOR CHIDAMIDE IN ACUTE PROMYELOCYTIC LEUKEMIA VARIANTS
EHA Library, Nannan Liu, 294445
THE M6A RNA METHYLTRANSFERASE METTL3/METTL14 PROMOTES LEUKEMOGENESIS THROUGH THE MDM2/P53 PATHWAY IN ACUTE MYELOID LEUKEMIA
EHA Library, Lina Sang, 294446
GENETIC AND PHENOTYPIC CHARACTERIZATION OF SUBCLONES IN ACUTE MYELOID LEUKEMIA
EHA Library, Francesca Tiso, 294447
MUTATIONAL SPECTRUM AND PROGNOSIS IN NRAS-MUTATED ACUTE MYELOID LEUKEMIA
EHA Library, Shujuan Wang, 294448
SORAFENIB AS MAINTENANCE FOR PREVENTING RELAPSE IN FLT3-ITD ACUTE MYELOID LEUKEMIA UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: AN RANDOMIZED, MULTICENTER, PHASE 3 TRIAL
EHA Library, Li Xuan, 294449
A RANDOMIZED DOUBLE-BLIND PHASE 3 TRIAL OF CYTARABINE WITH MDM2 INHIBITOR IDASANUTLIN OR PLACEBO IN RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA (R/R AML): PRIMARY ANALYSIS RESULTS OF THE MIRROS STUDY
EHA Library, Marina Y. Konopleva, 294450
TAGRAXOFUSP (SL-401), A CD123-DIRECTED THERAPY, IN PATIENTS WITH BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM (BPDCN): GENOMIC LANDSCAPE AND LONG-TERM RESULTS OF A LANDMARK CLINICAL TRIAL
EHA Library, Naveen Pemmaraju, 294451
CLINICAL OUTCOMES OF OLDER PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) RECEIVING HYPOMETHYLATING AGENTS: A LARGE POPULATION-BASED STUDY IN THE UNITED STATES
EHA Library, Rory Shallis, 294452
TIMING OF RESPONSE TO VENETOCLAX COMBINATION TREATMENT IN OLDER PATIENTS WITH ACUTE MYELOID LEUKEMIA
EHA Library, Brian Jonas, 294453
REMISSION AND SURVIVAL AFTER 90 MG VERSUS 60 MG DAUNORUBICIN IN 7+3 STANDARD INDUCTION FOR NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA: RESULTS FROM THE RANDOMIZED CONTROLLED SAL-DAUNODOUBLE TRIAL
EHA Library, Christoph Röllig, 294454
HIGHER PERCENTAGE OF LEUKEMIC STEM CELLS (LSC) AT DIAGNOSIS AND LSC MEASURABLE RESIDUAL STATUS (MRD) POSITIVITY PREDICTS INFERIOR OUTCOME IN ADULT ACUTE MYELOID LEUKEMIA (AML)
EHA Library, Chinmayee Nandkumar Kakirde, 294455
UPDATE FROM THE ONGOING PHASE I MULTINATIONAL STUDY OF MCLA-117, A BISPECIFIC CLEC12A X CD3 T-CELL ENGAGER, IN PATIENTS (PTS) WITH ACUTE MYELOGENOUS LEUKEMIA (AML)
EHA Library, John Mascarenhas, 294456
VALIDATION OF A GENE EXPRESSION BASED CLASSIFIER FOR THE PREDICTION OF RESISTANCE TO INDUCTION TREATMENT IN ACUTE MYELOID LEUKEMIA
EHA Library, Christian Moser, 294457
IVOSIDENIB IMPROVES OVERALL SURVIVAL RELATIVE TO STANDARD THERAPIES IN RELAPSED OR REFRACTORY MUTANT IDH1 AML: RESULTS FROM MATCHED COMPARISONS TO HISTORICAL CONTROLS
EHA Library, Peter Paschka, 294458
YOUNGER PATIENTS WITH NEWLY DIAGNOSED FLT3-MUTANT AML TREATED WITH CRENOLANIB PLUS CHEMOTHERAPY ACHIEVE DURABLE REMISSIONS
EHA Library, Boo Messahel, 294459
SEQUENTIAL FLT3 AND NGS BASED MUTATIONAL ANALYSIS IN RELAPSED FLT-3 POSITIVE AML POST FLT3- INHIBITORS BASED THERAPY.
EHA Library, Ahmad S Alotaibi, 294460
LONG-TERM SURVIVORS AND SAFETY BEYOND 1 YEAR OF GILTERITINIB THERAPY IN PATIENTS WITH FLT3-MUTATED RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA: FOLLOW-UP OF THE ADMIRAL PHASE 3 TRIAL
EHA Library, Alexander Perl, 294461
LOMUSTINE IS BENEFICIAL TO OLDER AML PATIENTS WITH AN ELN2017 ADVERSE RISK PROFILE AND AN INTERMEDIATE KARYOTYPE: RESULTS OF THE LAMSA-2007. A FILO TRIAL.
EHA Library, Eric DELABESSE, 294462
GLASDEGIB (GLAS) PLUS LOW-DOSE CYTARABINE (LDAC) IN AML OR MDS: BRIGHT AML 1003 FINAL REPORT AND 4-YEAR OVERALL SURVIVAL (OS) FOLLOW-UP.
EHA Library, Michael Heuser, 294463
OUTCOMES AND TREATMENT PATTERNS OF RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA WITHOUT TARGETED AGENTS: REAL-WORLD BENCHMARKS FOR FUTURE STUDIES FROM THE GERMAN SAL REGISTRY
EHA Library, Christoph Röllig, 294464
PROGNOSTIC AND THERAPEUTIC IMPLICATIONS OF MUTANT TP53 VARIANT ALLELIC FREQUENCY IN PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA
EHA Library, Nicholas Short, 294465
UPDATED RESULTS FROM A PHASE 1 FIRST-IN-HUMAN DOSE ESCALATION STUDY OF AMG 673, A NOVEL ANTI-CD33/CD3 BITE® (BISPECIFIC T-CELL ENGAGER) IN PATIENTS WITH RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA
EHA Library, Marion Subklewe, 294466
CHARACTERISTICS AND CLINICAL OUTCOMES OF MLL REARRANGEMENTS IN ADULTS WITH AML
EHA Library, Jabra Zarka, 294467
CC-486 MAINTENANCE THERAPY IS SAFE AND WELL TOLERATED IN PATIENTS AGED ≥75 YEARS WITH ACUTE MYELOID LEUKEMIA (AML) IN FIRST REMISSION FOLLOWING INDUCTION CHEMOTHERAPY: RESULTS FROM QUAZAR AML-001
EHA Library, Farhad Ravandi-Kashani, 294468
ZELLA-101: PHASE 1 STUDY OF ALVOCIDIB FOLLOWED BY 7+3 INDUCTION IN NEWLY DIAGNOSED AML
EHA Library, Joshua Zeidner, 294469
IS ASSESSMENT OF BONE MARROW DYSPLASIA STILL RELEVANT IN ACUTE MYELOID LEUKEMIAS IN THE GENOMICS ERA? A REPORT FROM THE ACUTE LEUKEMIA FRENCH ASSOCIATION
EHA Library, Matthieu Duchmann, 294470
PATTERNS OF CARE AND CLINICAL OUTCOMES WITH CYTARABINE-ANTHRACYCLINE INDUCTION CHEMOTHERAPY FOR AML PATIENTS IN THE US
EHA Library, Jan Philipp Bewersdorf, 294471
LONG-TERM FOLLOW-UP OF A PHASE 1/2 STUDY OF VENETOCLAX PLUS LOW-DOSE CYTARABINE IN PREVIOUSLY UNTREATED OLDER ADULTS WITH ACUTE MYELOID LEUKEMIA
EHA Library, Andrew Wei, 294472
FLUGAZA TRIAL: A PHASE III RANDOMIZED, OPEN LABEL STUDY COMPARING AZACITIDINE VERSUS FLUDARABINE AND CYTARABINE (FLUGA SCHEME) IN ELDERLY PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA
EHA Library, Susana Vives Polo, 294473
FIVE-YEAR FINAL RESULTS OF A PHASE 3 STUDY OF CPX-351 VERSUS 7+3 IN OLDER ADULTS WITH NEWLY DIAGNOSED HIGH-RISK/SECONDARY ACUTE MYELOID LEUKEMIA
EHA Library, Jeffrey Lancet, 294474
PRELIMINARY RESULTS OF A PHASE I/II STUDY OF AZACITIDINE, VENETOCLAX AND PEVONEDISTAT IN PATIENTS WITH SECONDARY ACUTE MYELOID LEUKEMIA WHO ARE UNFIT FOR INTENSIVE CHEMOTHERAPY
EHA Library, Nicholas Short, 294475
HLA-HAPLOIDENTICAL TRANSPLANTATION WITH REGULATORY AND CONVENTIONAL T CELL IMMUNOTHERAPY ERADICATES ACUTE MYELOID LEUKEMIA WITH HIGH-RISK CYTOGENETICS
EHA Library, Antonio Pierini, 294476
OVERALL SURVIVAL (OS) AND QUALITY OF LIFE (QOL) OF OLDER ADULTS DIAGNOSED WITH ACUTE MYELOID LEUKEMIA (AML) AND TREATED UNDER CONDITIONS OF USUAL CLINICAL PRACTICE: INTERIM REPORT OF THE SVLMA STUDY
EHA Library, Fernando Ramos, 294477
VALIDATION OF THE EUROPEAN LEUKEMIANET 2017 AML PROGNOSTIC CLASSIFICATION FOR PATIENTS WITH ACUTE MYELOID LEUKEMIA IN A RISK-ADAPTED TREATMENT PROTOCOL (CETLAM 2012)
EHA Library, Alex Bataller, 294478
ESCALATED DOSING SCHEDULES OF CC-486 ARE EFFECTIVE AND WELL TOLERATED FOR PATIENTS EXPERIENCING FIRST ACUTE MYELOID LEUKEMIA (AML) RELAPSE: RESULTS FROM THE PHASE III QUAZAR AML-001 MAINTENANCE TRIAL
EHA Library, Hartmut Döhner, 294479
OUTCOMES IN OLDER PATIENTS WITH HIGH-RISK/SECONDARY ACUTE MYELOID LEUKEMIA WHO ACHIEVED REMISSION WITH CPX-351 VERSUS 7+3 BUT DID NOT UNDERGO TRANSPLANT: PHASE 3 EXPLORATORY ANALYSIS
EHA Library, Tara L. Lin, 294480
IBRUTINIB ADDED TO 10-DAY DECITABINE FOR OLDER PATIENTS WITH AML AND HIGH-RISK MDS
EHA Library, Gerwin Huls, 294481
APPLICATION AND CLINICAL STUDY OF CLONAL HETEROGENEITY ANALYSIS IN ACUTE MYELOID LEUKEMIA
EHA Library, xiaodong lyu, 294482
PROGNOSTIC IMPACT OF TIME FROM DIAGNOSIS TO INITIAL TREATMENT FOR ACUTE MYELOID LEUKEMIA
EHA Library, Yoshimasa Kamoda, 294483
STANDARDIZED IDENTIFICATION OF MEASURABLE RESIDUAL DISEASE (MRD) BY MULTICOLOR FLOW CYTOMETRY (MFC) IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML)
EHA Library, Maximilian Roehnert, 294484
THE RELATIONSHIP BETWEEN PATIENT-REPORTED OUTCOMES AND CLINICAL OUTCOMES IN PATIENTS WITH FLT3-MUTATED RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA: RESULTS FROM THE PHASE 3 ADMIRAL STUDY
EHA Library, David Cella, 294485
PHASE 3 STUDY ASSESSING THE SAFETY AND EFFICACY OF MIDOSTAURIN IN YOUNGER AND OLDER PATIENTS WITH NEWLY DIAGNOSED, FLT3-MUTATED ACUTE MYELOID LEUKEMIA WHO ARE ELIGIBLE FOR 7+3 OR 5+2 CHEMOTHERAPY
EHA Library, Jorge Sierra, 294486
CHARACTERISTICS AND OUTCOME OF PATIENTS WITH ACUTE PROMYELOCYTIC LEUKEMIA TREATED WITH ARSENIC TRIOXIDE - AN INTERNATIONAL COLLABORATIVE STUDY
EHA Library, Sabine Kayser, 294487
EVOLVING TREATMENT PATTERNS AND OUTCOMES OF 3637 ≥60 YEAR-OLD PATIENTS WITH NEWLY DIAGNOSED AML REPORTED TO THE PETHEMA EPIDEMIOLOGIC REGISTRY.
EHA Library, Evelyn Acuna, 294488
EXPLORATORY ANALYSIS OF THE EFFICACY AND SAFETY OF CPX-351 VERSUS 7+3 BY EUROPEAN LEUKEMIANET (ELN) 2017 RISK GROUPS IN A PHASE 3 STUDY OF OLDER ADULTS WITH HIGH-RISK/SECONDARY ACUTE MYELOID LEUKEMIA
EHA Library, Thomas Prebet, 294489
CHANGES IN THE APPROACH TO CARE AND IN TREATMENT OUTCOMES IN ELDERLY ACUTE MYELOID LEUKEMIA PATIENTS IN THE ERA OF VENETOCLAX BASED REGIMENS: A SINGLE CENTER EXPERIENCE.
EHA Library, Miriam Neaman, 294490
ADDITION OF ANTI-CD33 MONOCLONAL ANTIBODY GEMTUZUMAB OZOGAMICIN TO FLAI INDUCTION SIGNIFICANTLY IMPROVES OUTCOME IN PATIENT AFFECTED BY FLT3-ITD MUTATED ACUTE MYELOID LEUKEMIA
EHA Library, Paola Minetto, 294491
A NOVEL MACHINE LEARNING DERIVED GENOMICS-BASED SCORING SYSTEM IS HIGHLY PREDICTIVE OF OUTCOME IN ACUTE MYELOID LEUKEMIA WITH RUNX1-RUNX1T1
EHA Library, Anam Shaikh, 294492
VENETOCLAX-BASED COMBINATIONS AS TREATMENT OF RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIAS AND HIGH-RISK MYELODYSPLASTIC SYNDROMES: A FRENCH EXPERIENCE
EHA Library, Tony Huynh, 294493
A PHASE-IB/II CLINICAL EVALUATION OF PONATINIB IN COMBINATION WITH AZACITIDINE IN FLT3-ITD POSITIVE ACUTE MYELOID LEUKAEMIA (ALLG AML M21)
EHA Library, David Kipp, 294494
IVOSIDENIB (IVO) PRIOR TO HEMATOPOIETIC CELL TRANSPLANT FOR PATIENTS WITH IDH1-MUTANT RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA (R/R AML)
EHA Library, Courtney D DiNardo, 294495
CDX REPORT PROGRAM - ASSESSMENT OF 311 CLINICAL REPORTS FROM 8 COUNTRIES TO ESTABLISH A REAL-WORD DATA SET OF THE CURRENT REPORTING PRACTICE FOR ONCO-HEMATOLOGY COMPANION DIAGNOSTICS (CDX) MARKERS
EHA Library, Sabit Delic, 294496
UPDATED ANALYSES OF A PHASE 1B/2 STUDY OF ONVANSERTIB, A PLK1 INHIBITOR, IN COMBINATION WITH DECITABINE IN PATIENTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA
EHA Library, Amer Zeidan, 294497
IADADEMSTAT SHOWS EFFICACY IN COMBINATION WITH AZACITIDINE IN ELDERLY AML PATIENTS: ALICE TRIAL
EHA Library, Olga Salamero, 294498
GLASDEGIB PLUS AZACITIDINE IN PATIENTS WITH UNTREATED HIGHER-RISK MYELODYSPLASTIC SYNDROMES, ACUTE MYELOID LEUKEMIA AND CHRONIC MYELOMONOCYTIC LEUKEMIA: MARROW RECOVERY AND TRANSFUSION INDEPENDENCE
EHA Library, Amer Zeidan, 294499
UPDATE ON PRELIMINARY RESULTS FROM PHASE 1 FIRST-IN-HUMAN DOSE ESCALATION STUDY OF AMG 330 IN PATIENTS WITH RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA (R/R AML)
EHA Library, Farhad Ravandi-Kashani, 294500
CHARACTERISTICS AND TREATMENT STRATEGIES OF SECONDARY ACUTE MYELOID LEUKEMIA PATIENTS: DATA FROM THE PETHEMA AML EPIDEMIOLOGIC REGISTRY
EHA Library, David Martinez-Cuadron, 294501
CLEARANCE OF PHENOTYPICALLY DISTINCT FLT3-ITD AND FLT3-TKD CLONES BY TREATMENT WITH CRENOLANIB AND CHEMOTHERAPY AS DETECTED BY LONGITUDINAL SINGLE-CELL DNA SEQUENCING ANALYSIS
EHA Library, Boo Messahel, 294502
CLINICAL AND RADIOLOGIC RESOLUTION OF INFECTIONS DURING TREATMENT WITH MBIL-21-EXPANDED CD56BRIGHT/CD16BRIGHT NK CELLS IN PATIENTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA (R/R AML)
EHA Library, Lucia Silla, 294503
CHEMOTHERAPY-FREE STRATEGY OF ALL-TRANS RETINOIC ACID AND ARSENIC TRIOXIDE FOR ALL-RISK ACUTE PROMYELOCYTIC LEUKEMIA
EHA Library, Huaiyu Wang, 294504
RISK STRATIFICATION OF CYTOGENTICALLY-NORMAL ACUTE MYELOID LEUKEMIA WITH BIALLELIC CEBPA MUTATIONS BASED ON NOMOGRAM MODEL
EHA Library, Li-Xin Wu, 294505
DATA FROM FRENCH NAMED PATIENT PROGRAM OF QUIZARTINIB IN RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA
EHA Library, Sarah Bertoli, 294506
FIRST-IN-HUMAN STUDY OF A TRAIL RECEPTOR AGONIST FUSION PROTEIN, EFTOZANERMIN ALFA, IN PATIENTS WITH RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA AND DIFFUSE LARGE B-CELL LYMPHOMA
EHA Library, Mojca Jongen-Lavrencic, 294507
VENETOCLAX IN COMBINATION WITH LOW DOSE CYTARABINE, ACTINOMYCIN D AND DONOR LYMPHOCYTE INFUSIONS FOR EARLY RELAPSE OF ACUTE MYELOID LEUKEMIA AFTER ALLOGENEIC STEM CELL TRANSPLANTATION
EHA Library, Andrius Žučenka, 294508
PROGNOSTIC IMPACT OF DNA METHYLATION MODIFIER MUTATIONS ALLELIC RATIO IN FLT3-ITD ALLELIC RATIO STATUS OF ACUTE MYELOID LEUKEMIA.
EHA Library, Satoshi Wakita, 294509
TRENDS IN FIRST-LINE THERAPY CHOICE IN PATIENTS ≥ 65 YEARS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA BETWEEN 2011 AND 2018: RESULTS FROM THE AMLCG REGISTRY
EHA Library, Andreas Rank, 294510
LONG TERM DATA DEMONSTRATING INFERIOR SURVIVAL OUTCOMES IN PATIENTS WITH MYELOID SARCOMA
EHA Library, Claire Andrews, 294511
RISK-ADAPTED THERAPY BASED ON ARSENIC TRIOXIDE AND ATRA IN DE NOVO AND RELAPSED APL PATIENTS.
EHA Library, Vera Troitskaya, 294512
SAFETY AND EFFICACY OF MUTANT IDH1 INHIBITOR BAY1436032 IN SUBJECTS WITH IDH1-MUTATED AML
EHA Library, Michael Heuser, 294513
PRE-CONDITIONING INTERVENTION IN PATIENTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA WHO UNDERWENT ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION: A KSGCT MULTICENTER ANALYSIS
EHA Library, Takayoshi Tachibana, 294515
RESULTS FROM A PHASE 1 DOSE-FINDING STUDY OF CC-90009, A CEREBLON E3 LIGASE MODULATOR AND FIRST-IN-CLASS GSPT1 DEGRADER, IN PATIENTS (PTS) WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA (RR AML)
EHA Library, Amer M. Zeidan, 294516
TREATMENT OF AML WITH T(8;21) AND KIT MUTATIONS OR FLT3-ITD USING CHEMOTHERAPY PLUS MIDOSTAURIN: RESULTS OF THE MIDOKIT TRIAL
EHA Library, Christoph Röllig, 294517

Anonymous User Privacy Preferences

Strictly Necessary Cookies (Always Active)

MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.


Performance Cookies

Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.



Google Analytics is used for user behavior tracking/reporting. Google Analytics works in parallel and independently from MLG’s features. Google Analytics relies on cookies and these cookies can be used by Google to track users across different platforms/services.



{$cookies-google-tag-manager-description}


Save Settings